Edition:
United States

MacroGenics Inc (MGNX.OQ)

MGNX.OQ on NASDAQ Stock Exchange Global Select Market

17.93USD
24 Mar 2017
Change (% chg)

$0.05 (+0.28%)
Prev Close
$17.88
Open
$17.97
Day's High
$18.03
Day's Low
$17.68
Volume
64,802
Avg. Vol
100,555
52-wk High
$33.30
52-wk Low
$15.57

Latest Key Developments (Source: Significant Developments)

Macrogenics provides announces 2016 financial results
Tuesday, 28 Feb 2017 04:01pm EST 

Macrogenics Inc : Macrogenics provides update on corporate progress and 2016 financial results .Macrogenics - expects its current cash, cash equivalents, anticipated funding under current collaborations, should fund co's operations through late 2018.  Full Article

First dosing of Pfizer DART candidate in phase 1 study triggers milestone payment to MacroGenics
Tuesday, 10 May 2016 07:30am EDT 

MacroGenics Inc : Commencement of phase 1 study triggers a $2 million milestone payment to MacroGenics under companies' October 2010 agreement. . Pfizer recently dosed a first patient in phase 1 clinical study of PF-06671008, which targets P-cadherin and CD3 .First dosing of Pfizer DART candidate in phase 1 study triggers milestone payment to MacroGenics.  Full Article

MacroGenics Inc and Merck to collaborate on Immuno-Oncology study
Thursday, 22 Oct 2015 07:30am EDT 

MacroGenics Inc and Merck:Says collaboration to evaluate the combination of MacroGenics' anti-HER2 product candidate, margetuximab, with Merck's anti-PD-1 therapy, KEYTRUDA, in a Phase 1b/2 clinical trial in patients with advanced gastric cancer.Says agreement is between MacroGenics and Merck, through a subsidiary.Additional details were not disclosed.  Full Article

MacroGenics announces pricing of public offering of common stock
Tuesday, 14 Jul 2015 10:20pm EDT 

MacroGenics Inc:Announces the pricing of an underwritten public offering of 3,525,000 shares of its common stock at a public offering price of $37.00 per share, before underwriting discounts.Says in addition, MacroGenics has granted the underwriters a 30-day option to purchase up to an additional 528,750 shares of common stock.Says Morgan Stanley, Citigroup and Leerink Partners are acting as joint book-running managers of the proposed offering. Stifel is acting as lead manager, and Wedbush PacGrow and Roth Capital Partners are acting as co-managers.Says the offering is expected to close on or about July 20, subject to customary closing conditions.Anticipates the total gross proceeds from the offering will be about $130.4 million, excluding any exercise of the underwriters' option to purchase additional shares.Intends to use the proceeds of this offering to fund further expansion of its manufacturing capacity, initial development of the first few of its previously undisclosed immune checkpoint-based product candidates.Says for further investment in the development of its current product pipeline, other research and development programs, in-licensing or acquiring other products or technologies, or for general corporate purposes, including working capital.  Full Article

MacroGenics announces proposed public offering of common stock
Monday, 13 Jul 2015 04:01pm EDT 

MacroGenics:Says offering 3.3 mln common shares.MacroGenics also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering.Morgan Stanley, Citigroup and Leerink Partners are acting as joint book-running managers of the proposed offering.Stifel is acting as lead manager.  Full Article

More From Around the Web

BRIEF-Macrogenics provides announces 2016 financial results

* Macrogenics provides update on corporate progress and 2016 financial results